Claims
- 1. A pharmaceutical composition in dosage unit form comprising a pharmaceutical carrier and an effective smooth muscle relaxant amount of a compound selected from the group consisting of 10-imidoylacridans having the formula ##STR5## and a non-toxic pharmaceutically acceptable acid addition salt thereof wherein
- X represents a divalent methylene radical of the formula
- --C(Z.sub.1 Z.sub.2)--
- wherein
- Z.sub.1 and Z.sub.2 are independently selected from hydrogen or straight chain lower alkyl of from 1 to 4 carbon atoms inclusive;
- Y represents hydrogen, trifluoromethyl, halogen, dihalogen, lower alkyl of 1 to 4 carbon atoms inclusive, lower alkoxy of 1 to 4 carbon atoms inclusive; and is selected from the group consisting of ##STR6## wherein R.sub.1 is lower alkyl of 1 to 4 carbon atoms inclusive or cycloalkyl of 3 to 5 carbon atoms inclusive;
- R.sub.2 is hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive;
- R.sub.3 and R.sub.4 are independent members selected from the group consisting of hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive;
- n is the integer of 3 to 5.
- 2. The composition of claim 1 in which the active ingredient is 10-[2-(1-pyrrolinyl)]acridan or a pharmaceutically acceptable acid addition salt thereof.
- 3. The composition of claim 1 in which the active ingredient is 10-[2-(5-methyl-1-pyrrolinyl)]acridan or a pharmaceutically acceptable acid addition salt thereof.
- 4. The composition of claim 1 in which the active ingredient is 10-[2-(5,5-dimethyl-1-pyrrolinyl)]acridan or a pharmaceutically acceptable acid addition salt thereof.
- 5. The composition of claim 1 in which the active ingredient is 10-3,4,5,6-tetrahydro-2-pyridyl)acridan or a pharmaceutically acceptable acid addition salt thereof.
- 6. The composition of claim 1 in which the active ingredient is 10-[(isopropylimino)methyl]acridan or a pharmaceutically acceptable acid addition salt thereof.
- 7. The composition of claim 1 in which the active ingredient is 9,9-dimethyl-10-(5-methyl-1-pyrrolin-2-yl)acridan or a pharmaceutically acceptable acid addition salt thereof.
CROSS-REFERENCE TO RELATES APPLICATIONS
This application is a divisional of co-pending application Ser. No. 812,292, filed July 1, 1977, now U.S. Pat. No. 4,094,981, which in turn is a divisional of then co-pending application Ser. No. 670,600, filed Mar. 26, 1976, and now U.S. Pat. No. 4,046,891, which in turn is a divisional of then co-pending application Ser. No. 561,462, filed Mar. 24, 1975, and now U.S. Pat. No. 3,962,252, which in turn is a divisional of then co-pending application Ser. No. 336,671, filed Feb. 28, 1973, and now U.S. Pat. No. 3,888,852.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3498986 |
Meisels et al. |
Mar 1970 |
|
3770727 |
Brack |
Nov 1973 |
|
Non-Patent Literature Citations (1)
Entry |
Moskoukina et al., Chem. Abst. vol. 73-14649n (1970). |
Divisions (4)
|
Number |
Date |
Country |
Parent |
812292 |
Jul 1977 |
|
Parent |
670600 |
Mar 1976 |
|
Parent |
561462 |
Mar 1975 |
|
Parent |
336671 |
Feb 1973 |
|